Testing TQ05105 for intermediate/high-risk myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with a life expectancy of at least 6 months
- Confirmed diagnosis of primary myelofibrosis or myelofibrosis that developed after polycythemia vera or essential thrombocythemia
- Disease classified as intermediate or high risk on a standard scoring system
- Adequate kidney and liver function; blood cell counts within acceptable ranges
- Willing to use effective birth control during the study and for 6 months after; females cannot be pregnant or breastfeeding
- No prior stem-cell transplant, or autologous transplant must be at least 3 months prior
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This study tests how a tablet called TQ05105 is processed in people with different levels of liver function. It helps doctors understand the right dose for patients with liver problems.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.